Silicon Investor - Pennies Arent Dead

[rdkflorida2] SURY>>>"Potential". News could push this penny play to $1s.

rdkflorida2 — 4/13/2026 8:54:25 AM

[Damián] Elite Pharmaceuticals, Inc. Hello, I have heard from this company and it looks...

Damián — 3/15/2026 6:16:56 AM

Elite Pharmaceuticals, Inc.

Hello, I have heard from this company and it looks too good to be true.

A guy was saying that this company has 140 million in annual income. This company only has 68 employees so they earn 2 million approx per head. Also, I heard that they could be bought by Pfizer or some of the biopharma giants easily.

Let me know what you think. I heard this all from internet and could be wrong.

Thanks.

[rdkflorida2] We may hear more about lithium and rare earth/minerals in speech tonight. Plus ...

rdkflorida2 — 2/24/2026 10:30:36 AM

We may hear more about lithium and rare earth/minerals in speech tonight. Plus China may retaliate against the new 15% tariffs by cutting off U.S. Just a FYI. RDK

[rdkflorida2] LTUM>>>>News. Look for all lithium plays to move up. Trump launches $12bin min...

rdkflorida2 — 2/2/2026 4:32:22 PM

LTUM>>>>News. Look for all lithium plays to move up.

Trump launches $12bin minerals stockpile to boost US manufacturing, counter China

[rdkflorida2] RUBI.....Spin off from TOPS. IMHO, very undervalued at this time. Company look...

rdkflorida2 — 11/5/2025 10:35:04 AM

RUBI.....Spin off from TOPS. IMHO, very undervalued at this time. Company looks like it is both a value and growth play. Picked up some shares today.

[getlouied] $CBDL CBD Life Sciences Inc. (CBDL) Launches First-of-Its-Kind Mushroom-Infused ...

getlouied — 10/21/2025 8:32:50 AM

$CBDL CBD Life Sciences Inc. (CBDL) Launches First-of-Its-Kind Mushroom-Infused "Dubai Chocolate Bar"

accessnewswire.com

Dubai's luxury chocolate market-valued at over $1.5 billion and growing 6.8% annually-meets the $35 billion global mushroom supplement boom, creating a major new revenue stream for CBDL.

SCOTTSDALE, ARIZONA / ACCESS Newswire / October 21, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL), through its wholly owned subsidiary CBD Vault, is proud to announce the official launch of its Mushroom-Infused Dubai Chocolate Bar, a premium fusion of functional wellness and luxury indulgence.

Inspired by the decadent chocolate culture of Dubai, each bar combines pistachio-filled layers with rich, velvety chocolate and is infused with Cordyceps and Reishi mushroom extracts, two of the most powerful adaptogens known to enhance focus, immunity, and stamina. This marks one of the first products in the world to successfully merge functional mushrooms with Dubai-style luxury confectionery, placing CBDL at the forefront of a rapidly evolving edible wellness revolution.

A Billion-Dollar Intersection of Wellness and Luxury

The Dubai chocolate market alone generates more than $1.5 billion annually and continues to surge as consumers seek ultra-premium confectionery experiences. Meanwhile, the global functional mushroom market is forecasted to reach $35 billion by 2030, growing at a CAGR of 10.8%, fueled by demand for natural health boosters and cognitive enhancers.

By strategically combining these two sectors, CBDL is positioning itself for exponential growth, introducing a new revenue vertical that blends wellness benefits, cultural sophistication, and mass appeal.

A Game-Changing Product for CBDL's Expansion

"We wanted to bring something extraordinary to the table-a product that tastes world-class and performs like a supplement," said a CBDL spokesperson. "By infusing our signature mushroom blend into a pistachio-filled Dubai-style chocolate bar, we're creating not just a treat but a wellness experience. This product can open doors across luxury retail, health stores, airports, and online marketplaces, while significantly enhancing shareholder value."

CBD Life Sciences plans to integrate the Mushroom-Infused Dubai Chocolate Bar into its Mushroom Madness product line and will pursue distribution through both international wellness chains and domestic retail partners. The company believes this launch could drive strong recurring revenue in Q4 2025 and throughout 2026, as the brand expands its footprint across the luxury wellness market.

[getlouied] $CBDL CBD Life Sciences Inc. (CBDL) Lands Major Order from Bronx Dispensary "S...

getlouied — 10/14/2025 10:18:27 AM

$CBDL CBD Life Sciences Inc. (CBDL) Lands Major Order from Bronx Dispensary "Smoking Scholars," Signaling Explosive Growth Ahead for CBD-Infused Drinks Division

accessnewswire.com

Strong consumer demand and rapid market adoption drive CBDL's beverage expansion as top-selling CBD Lemonade, Raspberry Lemonade, and Lavender Lemonade hit the shelves of Smoking Scholars in New York City - setting the stage for record-breaking revenue in Q4 and beyond.

SCOTTSDALE, AZ / ACCESS Newswire / October 14, 2025 / CBD Life Sciences Inc. (OTC:CBDL), parent company of CBD Vault, proudly announces a major order from Smoking Scholars Dispensary, located at 784 Allerton Avenue, Bronx, NY 10467, marking a powerful expansion milestone in the company's rapidly growing beverage division.

Smoking Scholars, a premier dispensary serving thousands of customers across the Bronx and greater New York City area, has officially placed a large-scale order of CBDL's top-performing drinks, including:

16oz 50mg CBD Lemonade
16oz 25mg CBD Raspberry Lemonade
16oz 25mg CBD Lavender Lemonade
CBD-Infused Water

These top-tier beverages have quickly become fan favorites for their refreshing taste, balanced CBD infusion, and consistent quality. Their arrival at Smoking Scholars represents a major win for CBDL's East Coast expansion strategy, opening the door to recurring orders, brand visibility, and strategic retail placement in one of the most dynamic cannabis and wellness markets in the country.

The CBD beverage market continues to show unprecedented growth, projected to exceed $4.2 billion by 2030 with a compound annual growth rate (CAGR) of over 25%. With consumer interest surging in functional wellness drinks, CBDL's infused beverage line is strategically positioned to capture a significant share of this booming sector.

"This is an extremely exciting development for the company," said a spokesperson for CBD Life Sciences Inc. "The Bronx represents one of the most competitive and lucrative retail markets in the U.S. - and getting our beverages onto Smoking Scholars' shelves proves that CBDL is no longer just participating in the CBD industry, we're leading a movement. The momentum behind our CBD drinks has been phenomenal, and we're already in discussions with several additional dispensaries eager to join the wave."

This major order also reflects the direct results of CBDL's participation at the NECANN Cannabis Conference, where the company showcased its expanding product portfolio to hundreds of retail buyers, distributors, and dispensary owners. The event has already produced multiple partnership leads and letters of intent, with Smoking Scholars being one of several new accounts developed through these networking efforts.

The partnership is expected to generate substantial recurring revenue through bulk beverage orders, with projections indicating six-figure monthly sales potential as the company onboards additional dispensary partners. Beyond this milestone, CBDL has ongoing negotiations with retailers and dispensaries across New Jersey and Pennsylvania, creating a growing regional pipeline of future sales and distribution opportunities.

As the functional beverage space continues to gain mainstream traction, CBDL's infused drink line stands out for its clean ingredients, exceptional flavor, and reliable dosage consistency - all qualities that drive strong customer retention and retailer reorders.

[rdkflorida2] LTUM>>>Big move today. Could go into the $1.00s.

rdkflorida2 — 10/2/2025 3:19:21 PM

[getlouied] $CBDL CBD Life Sciences Inc. (CBDL) Secures Landmark Agreement with Bronx Powerh...

getlouied — 9/30/2025 8:19:41 AM

$CBDL CBD Life Sciences Inc. (CBDL) Secures Landmark Agreement with Bronx Powerhouse Dispensary Smoking Scholars

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cbd-life-sciences-inc.-cbdl-secures-landmark-agreement-with-bronx-pow-1077348

With New York dispensaries projected to surpass $4.4 billion in annual sales by 2027, CBDL secures a transformative partnership poised to generate multi-million-dollar revenues and accelerate nationwide expansion.

SCOTTSDALE, AZ / ACCESS Newswire / September 30, 2025 / CBD Life Sciences Inc. (OTC:CBDL), through its operating subsidiary CBD Vault, today announced a game-changing client acquisition with Smoking Scholars, a premier dispensary located at 784 Allerton Ave in the Bronx, New York. This strategic agreement, finalized following CBDL's successful showcase at the NECANN New Jersey Conference, positions the Company to capture a powerful share of the booming New York cannabis and CBD marketplace.

Smoking Scholars is a multi-million-dollar enterprise with an elite client roster stretching across the United States. Their decision to bring CBD Vault into their packed product catalog is a resounding endorsement of CBDL's premium formulations and an entry point into one of the most competitive and rewarding markets in the nation.

Under the agreement, Smoking Scholars has placed a significant initial order featuring:

CBD Pain Relief Cream
CBD Massage Oil
Full Spectrum Gummies
CBD Infused Tea
Reishi Mushroom Face Cream

This order alone has the potential to generate hundreds of thousands in revenue within the next 12 months, with repeat orders expected as consumer demand for CBD wellness products accelerates. Importantly, this is just one of many dispensaries CBDL is securing as part of its rapid nationwide expansion.

Tapping Into One of America's Fastest-Growing Markets

New York's cannabis industry is undergoing explosive growth, with annual dispensary sales projected to exceed $4.4 billion by 2027. Consumer spending in the state is surging across both recreational and wellness categories, creating unparalleled opportunities for innovative brands like CBD Vault.

"Securing a powerhouse partner like Smoking Scholars is a watershed moment for our Company," said Lisa Nelson, President & CEO of CBD Life Sciences Inc. "This agreement validates our products on a national scale and gives us a strategic foothold in one of the most high-value markets in the country. For our shareholders, this deal represents not just immediate revenue but the beginning of long-term exponential growth."

Building Momentum from NECANN

CBDL's presence at NECANN continues to pay dividends. In addition to the Smoking Scholars partnership, management is actively engaged with multiple high-profile dispensaries across the Northeast, creating a robust pipeline of potential deals. The Company anticipates announcing additional agreements in the near future, further expanding its footprint and accelerating revenues.

Positioned for Long-Term Growth

With a diverse portfolio spanning pain management, relaxation, and skincare, CBDL is uniquely positioned to meet surging consumer demand for CBD and mushroom wellness products. Analysts forecast the global CBD market to grow at a CAGR of over 31% through 2030, with U.S. demand driving much of that expansion. By aligning with large-scale dispensary partners, CBDL is executing a strategy designed to capture substantial market share and deliver maximum shareholder value.

[getlouied] $CBDL CBD Life Sciences Inc. (CBDL) Announces LOI With New Jersey Dispensary, ...

getlouied — 9/23/2025 8:34:44 AM

$CBDL CBD Life Sciences Inc. (CBDL) Announces LOI With New Jersey Dispensary, Unlocking New Revenue Channels & Strategic Growth Opportunities

accessnewswire.com

Strategic collaboration expands CBDL's footprint in the booming East Coast cannabis market projected to surpass $33 billion by 2030, while strengthening retail distribution and cross-brand synergies

SCOTTSDALE, AZ / ACCESS Newswire / September 23, 2025 / CBD Life Sciences Inc. (OTC:CBDL), through its wholly owned subsidiary, CBD Vault, is proud to announce that it has entered into a Letter of Intent (LOI) with a licensed dispensary in New Jersey. This powerful agreement represents not just product placement, but a transformational partnership that creates two-way retail visibility, accelerates brand recognition, and opens the door to significant new revenue streams in one of the fastest-growing cannabis markets in the United States.

A Dual-Channel Partnership for Scalable Growth
Unlike conventional wholesale agreements, this LOI establishes a mutually beneficial distribution model. Under the terms, CBD Vault's flagship products - including the Company's industry-leading CBD Pain Relief Cream, Pain Relief Roll-On, 3000mg CBD Tinctures, and Delta-8 Gummies - will secure premium shelf space inside a bustling New Jersey dispensary. In return, select products from the dispensary's proprietary line will be stocked and featured in CBDL's own retail locations, creating a cross-pollination of audiences and expanding market reach for both companies.

This two-way approach not only diversifies CBDL's product mix but also positions the Company as a true collaborative partner within the cannabis ecosystem, enhancing long-term relationships and securing recurring sales channels.

Massive Market Potential on the East Coast
New Jersey's cannabis industry is emerging as a powerhouse. Recent research projects the state's market to surpass $2 billion annually by 2026, driven by both recreational legalization and strong consumer demand. The broader U.S. CBD and cannabis sector is forecasted to reach $33 billion by 2030, with wellness-driven CBD categories alone experiencing CAGR growth rates exceeding 14%.

For CBDL, this LOI is more than regional growth - it's an entry point into the lucrative East Coast corridor, which includes high-value markets such as New York, Pennsylvania, and Massachusetts. Establishing a foothold in New Jersey provides an anchor for potential multi-state expansion and positions the Company at the forefront of national growth trends.

Revenue Impact and Shareholder Value
Management anticipates that this strategic partnership could translate into seven-figure annualized revenues, while simultaneously boosting foot traffic and customer acquisition through reciprocal product placement. The cross-distribution model also mitigates risk by ensuring exposure to two distinct but synergistic consumer bases - dispensary shoppers and CBDL's loyal retail following.

"This LOI is more than just a retail deal - it's a strategic partnership that multiplies opportunities on both ends," stated Lisa Nelson, President & CEO of CBD Life Sciences Inc. "We are not only penetrating one of the strongest cannabis markets in the country, but we're also pioneering a distribution model that enhances shareholder value and sets the stage for exponential growth. We believe this collaboration will be the first of many as we aggressively expand across the East Coast."

Expanding Beyond New Jersey
CBDL views this New Jersey collaboration as a launchpad for broader growth. The Company plans to replicate this model with additional dispensaries and retailers in high-demand markets, creating a scalable blueprint for expansion. By leveraging strong brand equity, product innovation, and investor backing, CBDL is strategically positioned to capture substantial market share as the industry continues its rapid ascent.

[getlouied] $CBDL CBD Life Sciences Inc. (CBDL) Huge Momentum Following NECANN New Jersey 20...

getlouied — 9/16/2025 8:14:35 AM

$CBDL CBD Life Sciences Inc. (CBDL) Huge Momentum Following NECANN New Jersey 2025

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cbd-life-sciences-inc.-cbdl-huge-momentum-following-necann-new-jersey-1073910

The U.S. marijuana dispensary market is projected to generate over $31.8 billion annually by 2025, creating multi-million-dollar opportunities for CBDL through dispensary partnerships and large-scale beverage distribution in sports stadiums nationwide.

SCOTTSDALE, ARIZONA / ACCESS Newswire / September 16, 2025 / CBD Life Sciences Inc. (OTC:CBDL), the parent company of The CBD Vault, is proud to announce significant progress following its recent participation at the NECANN New Jersey 2025 Cannabis Conference, one of the largest cannabis trade shows in the country. This high-visibility event has positioned CBDL at the forefront of the industry, paving the way for Letters of Intent (LOIs) and advanced negotiations with five major dispensaries across Pennsylvania & New Jersey.

These five dispensaries collectively represent access to thousands of retail customers and the potential for multi-million-dollar annual revenue contributions once contracts are finalized. By strategically aligning with dispensary operators who have strong market penetration and loyal customer bases, CBDL expects to accelerate its revenue growth trajectory while cementing itself as a recognized provider of premium CBD wellness products.

Beyond dispensaries, CBDL is actively advancing its proprietary beverage portfolio. The CBD Vault's CBD Seltzer and CBD Lemonade Drink are already generating strong interest and are slated for distribution in football and baseball stadiums. With sports venues averaging tens of thousands of attendees per game, these distribution channels are poised to expose CBDL's brand to millions of consumers annually. The ability to penetrate this mainstream market represents a transformational growth catalyst, bridging the gap between the cannabis sector and traditional consumer packaged goods.

Why NECANN Matters for CBDL:

NECANN is one of the nation's most respected cannabis conferences, drawing investors, dispensary owners, and operators from across the U.S.
The event gave CBDL the opportunity to showcase its full product suite, including topicals, tinctures, edibles, and beverages, while networking directly with decision-makers.
Unlike smaller trade shows, NECANN provides the credibility and scale needed to attract institutional-level buyers and partners.

The Cannabis Market Outlook:

According to BDSA, legal cannabis dispensaries in the U.S. are on track to generate over $31.8 billion in revenue by 2025.
CBD-infused beverages are projected to be one of the fastest-growing categories in the industry, with estimates showing a compound annual growth rate (CAGR) exceeding 20%.
By securing both dispensary shelf space and stadium distribution, CBDL is positioned to capture value across multiple billion-dollar verticals simultaneously.

"Our NECANN New Jersey experience was more than just networking - it was a launching pad," said Lisa Nelson, President & CEO of CBD Life Sciences Inc. "The five dispensaries we are now engaged with each have the ability to add meaningful revenue to our bottom line. At the same time, our CBD seltzer and lemonade beverages are gaining traction with stadium operators, creating one of the most exciting growth opportunities our company has ever seen. We believe this dual approach - dispensary expansion and mass-market beverage distribution - sets CBDL apart as a true leader in the space."

For shareholders, these developments underscore CBDL's scalable growth model. By diversifying distribution between regulated cannabis channels and mainstream consumer venues, the Company is uniquely positioned to benefit from both the rapid expansion of legal cannabis and the surging demand for functional wellness beverages.

CBD Life Sciences Inc. will continue to update investors as agreements with dispensaries are finalized and beverage rollouts progress. Additional announcements are expected in the coming weeks as the Company executes its aggressive expansion strategy.

[rdkflorida2] CNRC>>>>PPS moving up on big volume, "again". Could be they hit on a big deposi...

rdkflorida2 — 9/15/2025 3:26:58 PM

CNRC>>>>PPS moving up on big volume, "again". Could be they hit on a big deposit/reserve. Just a FYI.

[rdkflorida2] Over 10X avg. daily volume today. News pending? Did Kubera find a large deposi...

rdkflorida2 — 9/11/2025 4:08:10 PM

Over 10X avg. daily volume today. News pending? Did Kubera find a large deposit/reserve?

[rdkflorida2] CNRC>>>Kubera detection technology has pinpointed areas showing returns of possi...

rdkflorida2 — 9/6/2025 6:38:27 PM

CNRC>>>Kubera detection technology has pinpointed areas showing returns of possible reserves. Sites being prepared for drilling as I type. Any significant finds and the PPS is going to soar. RDK

[getlouied] $CBDL CBD Life Sciences Inc. (CBDL) Announces President Trump Confirms Marijuana...

getlouied — 9/3/2025 1:06:26 PM

$CBDL CBD Life Sciences Inc. (CBDL) Announces President Trump Confirms Marijuana Rescheduling Is Under Consideration

accessnewswire.com

"A shift to Schedule III could unlock a $30+ billion market, eliminate crippling 280E tax burdens, unleash institutional investment, and set the stage for explosive industry-wide growth."

SCOTTSDALE, ARIZONA / ACCESS Newswire / September 3, 2025 / CBD Life Sciences Inc. (OTC:CBDL), a leader in the development and sale of high-quality CBD and wellness products, is pleased to announce that President Donald Trump has confirmed his administration is actively considering the rescheduling of marijuana under the Controlled Substances Act. This announcement, highlighted in a recent JD Supra legal analysis, signals what may be the most pivotal regulatory moment in the history of the cannabis industry.

The administration is reviewing a proposal to reclassify cannabis from Schedule I to Schedule III, which would:

Deliver billions in tax relief: The elimination of IRS Section 280E restrictions would allow cannabis companies to deduct ordinary business expenses, improving net margins by double digits and freeing up billions in reinvestment capital across the sector.
Unlock capital markets: Banks, lenders, and institutional investors-previously sidelined due to regulatory risk-would gain clearance to enter the cannabis space, fueling an unprecedented wave of financing, credit, and equity growth.
Elevate cannabis as legitimate medicine: Federal recognition of marijuana's medical value would boost physician confidence, accelerate clinical trials, and enhance credibility with healthcare providers and patients alike.
Catalyze M&A and consolidation: Regulatory clarity would supercharge mergers, acquisitions, and strategic alliances, positioning leading companies like CBDL to seize early-mover advantage.
Ignite investor sentiment: Cannabis equities have already rallied on rescheduling optimism. A formal reclassification could spark another surge, creating generational wealth opportunities for early shareholders.

Why This Matters for CBD Life Sciences Inc.

CBD Life Sciences Inc. stands at the forefront of this coming wave. With proven retail traction, recent approvals for sale on Walmart Marketplace, and a growing pipeline of CBD and wellness innovations, the company is positioned to scale rapidly once federal restrictions ease.

"This is the moment we've been preparing for," said Lisa Nelson, President & CEO of CBD Life Sciences Inc. "The rescheduling of cannabis would remove historic barriers that have limited our industry's growth. For CBDL, it means the ability to expand faster, compete more effectively, and deliver greater long-term value for our shareholders."

Investor Highlights

President Trump confirms marijuana rescheduling is under active review.
Federal reform could unleash a $30+ billion U.S. cannabis market opportunity.
IRS 280E tax relief expected to save the industry billions annually.
Expanded access to institutional capital, banking, and financing.
Growing public approval of legalization with nearly 70% of Americans in support.
CBDL is already executing growth strategy with retail expansion and product innovation.

[getlouied] $CBDL CBD Life Sciences Inc. (CBDL) Announces Company Will Exhibit at the NECANN...

getlouied — 8/27/2025 8:30:58 AM

$CBDL CBD Life Sciences Inc. (CBDL) Announces Company Will Exhibit at the NECANN Cannabis Conference in Atlantic City, NJ

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cbd-life-sciences-inc.-cbdl-announces-company-will-exhibit-at-the-nec-1065839

NECANN New Jersey attracts over 5,000 industry leaders, features more than 200 exhibitors, and is ranked the 3rd largest B2B cannabis convention in the United States - positioning CBDL for unprecedented growth, revenue opportunities, and investor value.

SCOTTSDALE, ARIZONA / ACCESS Newswire / August 27, 2025 / CBD Life Sciences Inc. (OTC:CBDL), a trailblazer in the CBD and wellness industry, proudly announces that the Company will be exhibiting at the NECANN Cannabis Conference in Atlantic City, New Jersey, on September 5-6, 2025 at the New Jersey Convention Center. CBDL will showcase its flagship brand The CBD Vault at Booth 837, with exhibition hours scheduled for Friday (10AM-5PM) and Saturday (10AM-4PM).

Since its inception in 2019, NECANN New Jersey has rapidly ascended to become the largest and most influential gathering in the Mid-Atlantic cannabis sector, now ranked as the 3rd largest B2B cannabis convention nationwide. This year's event is expected to draw over 5,000 attendees, 200+ exhibitors, and more than 75 licensed cultivators, retailers, and brands, alongside investors, distributors, and industry thought leaders.

The 2025 event also introduces the first-ever New Jersey NECANN CUP, creating even greater visibility and opportunities for recognition among the cannabis industry's most innovative brands.

Why NECANN Matters for CBD Life Sciences Inc. and Its Shareholders

Exhibiting at NECANN is not just a branding opportunity, it is a gateway to accelerated growth, expanded partnerships, and revenue potential. For CBDL, this platform represents a multi-faceted opportunity to:

Strengthen Distribution Networks: Connect with hundreds of B2B buyers, wholesalers, and retailers who are actively seeking new product lines to carry.
Expand Market Reach: Enter the Mid-Atlantic market, one of the fastest-growing cannabis and CBD regions in the United States.
Accelerate Revenue Streams: NECANN is widely recognized as a hub for client acquisition, high-value deals, and long-term recurring revenue opportunities.
Attract New Investors & Strategic Partners: Build relationships with institutional and private investors looking to capitalize on the explosive CBD and cannabis industries.
Elevate Brand Visibility: Present The CBD Vault alongside 200+ of the industry's top innovators, ensuring the Company is positioned at the center of industry progress.

"NECANN is where opportunity meets execution," stated Lisa Nelson, President & CEO of CBD Life Sciences Inc. "We are honored to exhibit The CBD Vault at Booth 837, and we see this event as a critical inflection point for our Company. NECANN has proven to be a catalyst for partnerships, revenue growth, and investor confidence-and we are confident that the doors opened in Atlantic City will fuel CBDL's upward trajectory well into 2026 and beyond."

A Market Poised for Explosive Growth

The global CBD market continues to demonstrate exponential growth, with analysts projecting it to surpass $69 billion by 2029 at a compound annual growth rate (CAGR) exceeding 31%. In the United States alone, state-by-state legalization momentum is creating fertile ground for new partnerships, product innovation, and revenue expansion.

By aligning with NECANN, CBD Life Sciences Inc. is strategically positioning itself to capture market share in one of the nation's fastest-growing regions, while building long-term shareholder value through brand awareness, product adoption, and increased sales volume.

Commitment to Shareholders and Long-Term Value

CBDL's decision to exhibit at NECANN underscores the Company's unwavering commitment to delivering consistent growth, enhanced visibility, and expanded revenue channels for its shareholders. With every milestone-whether entering Walmart Marketplace, announcing new product launches, or securing retail expansion-CBDL continues to reinforce its reputation as a company on the rise.

The NECANN exhibition represents yet another bold step forward in this trajectory, one that is expected to create lasting impact for both current investors and potential future stakeholders.

Event Details:

New Jersey Convention Center - Atlantic City, NJ
September 5-6, 2025
Booth #837 - The CBD Vault
Friday: 10AM-5PM | Saturday: 10AM-4PM

For more information on NECANN New Jersey, please visit pr.report.

[rdkflorida2] Picked up some EONR today. Looks like it bottomed. Pick came from a friend. J...

rdkflorida2 — 7/30/2025 2:07:28 PM

Picked up some EONR today. Looks like it bottomed. Pick came from a friend. Just a FYI.

[rdkflorida2] CNRC>>>Kubera scanning has begun. Any new finds and PPS will soar, PR out today...

rdkflorida2 — 7/30/2025 12:47:04 PM

CNRC>>>Kubera scanning has begun. Any new finds and PPS will soar, PR out today.

[rdkflorida2] Kubera technology may find reserves missed in the past and at a lesser cost. Ju...

rdkflorida2 — 7/22/2025 11:53:12 AM

Kubera technology may find reserves missed in the past and at a lesser cost. Just a FYI.

[getlouied] $FBCD FBC Holding, Inc. (FBCD) Releases Shareholder Letter accessnewswire.com ...

getlouied — 7/15/2025 7:48:44 AM

$FBCD FBC Holding, Inc. (FBCD) Releases Shareholder Letter

accessnewswire.com

Streetwear Industry Forecast to Surpass $185 Billion by 2027, FBCD Positioned to Capitalize Amid Rapid Market Growth

SCOTTSDALE, ARIZONA / ACCESS Newswire / July 15, 2025 / FBCD, the parent company of Formrunner Apparel Inc., is proud to share an important update with shareholders regarding the company's rapid evolution, market positioning, and strategic initiatives. With consumer behavior shifting heavily toward culture-driven fashion and youth identity, FBCD stands at the intersection of retail innovation, streetwear dominance, and cultural influence.

The Market Opportunity: Streetwear Is No Longer a Trend - It's a Movement

According to recent market research, the global streetwear industry is projected to grow at a compound annual growth rate (CAGR) of 9.4%, reaching a market size of over $185 billion by 2027. The rise of celebrity collaborations, Gen Z spending power, and the surge in premium casualwear all contribute to this trajectory. Formrunner Apparel, under the FBCD umbrella, is uniquely positioned to tap into this momentum as both a brand and a retail platform.

Recent Developments Driving Shareholder Value

Over the past several months, FBCD has laid down a powerful foundation across digital, brand, and cultural verticals:

1. Launch of New Website and Expanded Digital Experience

Our upgraded e-commerce platform features a completely redesigned interface, faster load times, mobile-first optimization, and a curated rollout of our newest Formrunner Collection-including seasonal drops, accessories, and capsule pieces. This upgrade was designed for scale, supporting high-volume traffic, influencer campaigns, and future category launches.

2. Strategic Collaborations & Brand Partnerships

We are working with a growing list of established and emerging fashion brands to launch co-branded capsule drops that strengthen brand equity, generate cultural buzz, and drive high-margin, limited-inventory sales. These partnerships allow FBCD to remain flexible, tapped into niche communities, and highly reactive to cultural trends.

3. New Product Category Rollout - Hats & Headwear

FBCD is expanding into the lucrative headwear market with the launch of our premium Formrunner hat collection. This includes exclusive designs, fitteds, and co-branded pieces developed in collaboration with key tastemakers. Hats remain one of the most visible, high-velocity segments in streetwear, and we're entering with intention and creativity.

4. Athlete, Rapper & Celebrity Endorsement Campaigns

FBCD is in advanced talks with professional athletes, college sports figures, and influential music artists to join the Formrunner movement as official ambassadors. These authentic, culture-forward partnerships are designed to extend reach across sports, music, and youth culture-building brand resonance beyond the typical streetwear consumer.

5. Expansion Into Team Sports & Licensing Deals

We've initiated conversations with multiple professional and collegiate teams across football, basketball, and hockey to explore merchandise licensing, team partnerships, and crossover collections. This initiative places Formrunner Apparel at the intersection of lifestyle fashion and performance culture, unlocking major national visibility and new revenue streams.

6. Studio 22 as a Cultural Flagship

Rather than focusing on traditional retail expansion, FBCD operates Studio 22, a physical expression of our brand and culture. Located in Chandler Fashion Center and SanTan Village in Gilbert, AZ, these two flagship locations serve as experiential hubs for streetwear fans-housing not only Formrunner's collections but also a curated mix of local and high-end brands. These aren't just stores-they're cultural destinations and community incubators that deepen brand connection and generate organic growth.

Looking Ahead: FBCD's Vision for the Future

FBCD's rise is no accident. Every step is part of a strategic, multi-pronged growth plan-rooted in community, culture, and commerce. With a newly optimized digital platform, influential brand partners, celebrity collaborations in progress, and a strong foundation in experiential retail, FBCD is building a streetwear powerhouse that speaks to today's consumers and tomorrow's investors.

We remain focused on scaling with integrity, building value for shareholders, and shaping a lasting presence in one of the most dynamic fashion sectors in the world.

This is more than apparel. This is culture, ownership, and legacy.

We thank our investors and supporters for believing in the mission.

[Old Stock Collector] $ECOX News Out 1st news in 3 years morningstar.com

Old Stock Collector — 7/10/2025 9:15:01 AM

[Old Stock Collector] Affluence Corporation $AFFU Reports Over €6.4 Million in Signed Contracts for H...

Old Stock Collector — 7/7/2025 5:02:07 PM

Affluence Corporation $AFFU Reports Over €6.4 Million in Signed Contracts for H1 2025, Confirms Positive Momentum and Strategic Focus on U.S. Expansion
Stock price .0001 x .0002

accessnewswire.com

These are the web sites everyone should visit a couple of times a week at the very least. They hold the key to the future of Affluence and continue to add more and more information on what they are doing for us as shareholders. I added IoT in this as I firmly feel they will be the next acquisition the company intends to make

1. mingothings.com
Blog
mingothings.com

Note the above website is the main website but Mingothings has sub sites that do not link to their websites below:

arabia.mingothings.com
Blog
arabia.mingothings.com

smart-things.mingothings.com
Blog
smart-things.mingothings.com

NativeEdge Dell Technologies partner page MTi
delltechnologies.com

2 onemindng.com
Newest info:
onemindng.com

3 thethings.io
Blog
thethings.io

4. MTi on Linkedin: linkedin.com

5. OneMindNG Linkedin website: linkedin.com

6. thethings.io Linkedin: linkedin.com

[rdkflorida2] CNRC>>>>NEWS> "IF" they hit any oil/gas deposits with the new technology being ...

rdkflorida2 — 7/1/2025 11:28:44 AM

CNRC>>>>NEWS> "IF" they hit any oil/gas deposits with the new technology being deployed the PPS is going to soar. I've been in at .009 for sever hundred K. Just a FYI if anyone is interested.

[Giants1967] CNER bioEnergy Development Inc, (formerly China New Energy Group Company) create...

Giants1967 — 6/19/2025 8:26:16 AM

CNER bioEnergy Development Inc, (formerly China New Energy Group Company) creates two subsidiary companies to support growth
otcmarkets.com

[rdkflorida2] LTUM>>>Volume/Price continuing up. A good sign. Just a FYI.

rdkflorida2 — 6/11/2025 3:54:42 PM

[rdkflorida2] LTUM>>>On Bloomberg this a.m. Congress looking at passing "rare earths/minerals...

rdkflorida2 — 6/11/2025 10:02:20 AM

LTUM>>>On Bloomberg this a.m. Congress looking at passing "rare earths/minerals" act of some kind to get more in U.S. production. Could be big help to small/micro cap miners. Just a FYI.

[getlouied] $CBDL CBD Life Sciences Inc. (CBDL) Reports 1,502.30% Revenue Increase from Janu...

getlouied — 6/11/2025 8:19:06 AM

$CBDL CBD Life Sciences Inc. (CBDL) Reports 1,502.30% Revenue Increase from January to May 2025

accessnewswire.com

Achieving a five-month revenue growth equivalent to an annualized rate exceeding 4,000%, as the booming CBD and mushroom supplement markets-projected to reach $30 billion and $15 billion respectively by 2028-fuel strong consumer demand and industry expansion.

SCOTTSDALE, AZ / ACCESS Newswire / June 11, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL), a rising player in the natural health and wellness space, is proud to report a 1,502.30% increase in revenue from January through May of 2025 - a historic milestone for the company and a clear reflection of its expanding presence across retail, digital, and direct-to-consumer channels.

This performance marks the company's strongest run of sustained month-over-month revenue growth to date and comes as CBDL shifts from a single-category CBD company to a diversified wellness brand with products designed for modern performance, recovery, and cognitive support.

"This isn't just about selling more products - it's about becoming a health brand that consumers actively seek out," said Lisa Nelson, President & CEO of CBD Life Sciences Inc. "We've laid the foundation for scalable, repeatable success by combining innovation, access, and a strong identity in functional wellness."

Key Drivers Of Growth

National Retail Expansion & E-Commerce Ubiquity
CBDL's ability to meet consumers where they shop has been a major growth catalyst in 2025. The brand has successfully launched and scaled across high-traffic digital and physical platforms, including:

Walmart Marketplace: Multiple SKUs now available online, including CBDL's best-selling 3000MG Pain Relief Cream and skin care formulations.
DoorDash & Leafly: Products are accessible via local delivery in select markets, offering speed and convenience for customers.
Groupon: Strategic limited-time wellness deals driving strong first-time purchase activity and consumer discovery.
Shopify & Reddit: Expanded direct-to-consumer operations through Shopify, complemented by engagement in Reddit's niche wellness communities to boost brand awareness and customer acquisition.

Product Innovation: Functional Wellness for the Modern Consumer

CBDL's revenue growth closely aligns with its rapid innovation across plant-powered health categories. Beyond CBD, the company is gaining traction with functional and adaptogenic wellness products, including:

Mushroom Smoothies & Brain Support Blends: Featuring natural cognitive enhancers like lion's mane, reishi, and cordyceps, these smoothies support memory, mental clarity, and energy - and are appearing in local coffee shops and health stores.
Power+ Sexual Enhancement Supplement: A plant-based formula supporting male vitality, stamina, and circulation, quickly becoming a customer favorite.
Adaptogenic Mushroom Supplements: Proprietary blends designed to support immune health, stress reduction, and overall daily balance, harnessing reishi, chaga, lion's mane, and ashwagandha.

Strategic Vision & Responsible Growth

CBDL continues to invest in infrastructure, brand visibility, and strategic partnerships to ensure long-term sustainable growth. While focusing on the U.S. market currently, the company is evaluating future expansion opportunities and additional retail collaborations.

"Our focus remains on delivering real value through trusted products and accessible retail channels," added Nelson. "We are committed to building a wellness brand that serves consumers authentically while creating shareholder value."

[rdkflorida2] LTUM>>> Volume continues to increase. Just a FYI.

rdkflorida2 — 6/3/2025 3:45:13 PM

[getlouied] $CBDL CBD Life Sciences Inc. (CBDL) Releases New CBD Suppositories for Vaginal &...

getlouied — 6/3/2025 8:37:36 AM

$CBDL CBD Life Sciences Inc. (CBDL) Releases New CBD Suppositories for Vaginal & Rectal Relief

accessnewswire.com

CBDL Enters the $2.8 Billion Suppository Market with a First-of-Its-Kind Product - Tapping a High-Demand, Low-Competition Sector Poised for Transformational Growth

SCOTTSDALE, AZ / ACCESS Newswire / June 3, 2025 / CBD Life Sciences Inc. (OTC Pink:CBDL), a leader in the CBD wellness industry, proudly announces the launch of its groundbreaking line of CBD-infused vaginal and rectal suppositories. This innovative product is poised to transform the landscape of women's health by offering targeted relief for a myriad of conditions, including menstrual cramps, endometriosis, pelvic floor dysfunction, and gastrointestinal discomfort.

A Breakthrough for Localized, Fast-Acting Relief

Unlike oral CBD products, which must pass through the digestive system and may lose potency in the process, suppositories offer rapid absorption and superior bioavailability by delivering CBD directly into the bloodstream through the pelvic region or lower bowel.

This method allows patients to experience faster, more concentrated relief, particularly for conditions like:

Endometriosis and menstrual pain
Pelvic floor dysfunction
Prostatitis and hemorrhoids
Gastrointestinal disorders (IBS, IBD, Crohn's)
Chronic pelvic pain syndrome
Post-surgical recovery inflammation

By formulating this unique delivery system, CBD Life Sciences Inc. is opening the door to a broader application of CBD - bridging gaps in women's health, men's health, and gastrointestinal therapy.

The Science Behind the Relief

Recent studies show that CBD's anti-inflammatory, analgesic, and antispasmodic properties make it uniquely suited for conditions involving chronic pelvic or intestinal tension. In rectal use, CBD interacts with local CB1 and CB2 receptors in the digestive tract to reduce inflammation and modulate pain responses. For vaginal use, CBD has shown promise in reducing pelvic muscle tightness, cramping, and discomfort associated with reproductive or bladder-related disorders.

Market Potential: A Billion-Dollar Opportunity

The global pharmaceutical suppositories market was valued at approximately $1.6 billion in 2022 and is projected to reach $2.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.7% . North America holds the largest market share, accounting for nearly two-fifths of the global revenue.

CBD Life Sciences Inc.'s entry into this burgeoning market positions the company at the forefront of a healthcare revolution, offering investors a unique opportunity to capitalize on the intersection of natural wellness and women's health.

Local Medical Community Endorsement

Several healthcare professionals in Scottsdale, Arizona, have approached CBD Life Sciences Inc., expressing keen interest in the therapeutic potential of these suppositories for their patients. This local engagement underscores the product's relevance and anticipated impact in the medical community, further validating its market readiness and clinical significance.

[getlouied] CBD Life Sciences Inc. (CBDL) Announces New Powerful 500MG THC Delta-8 Gummy ht...

getlouied — 5/28/2025 1:55:35 PM

CBD Life Sciences Inc. (CBDL) Announces New Powerful 500MG THC Delta-8 Gummy

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cbd-life-sciences-inc.-cbdl-announces-new-powerful-500mg-thc-delta-8-1032515

With Delta-8 product revenue continuing to climb, CBDL introduces a lab-tested gummy formulation to meet surging demand in a market projected to exceed $2.1 billion by 2026.

SCOTTSDALE, AZ / ACCESS Newswire / May 28, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL), a rising force in the cannabinoid wellness industry, is proud to announce the latest addition to its growing Delta-8 product lineup: a premium, lab-tested Delta-8 THC gummy, developed in-house to ensure consistency, potency, and quality at every step.

Building on the success of its existing Delta-8 offerings, this new gummy marks another strategic milestone in CBDL's mission to dominate the cannabinoid edibles market. Crafted in a controlled lab environment, this new edible is designed for consumers who prioritize quality, effectiveness, and a clean, smooth Delta-8 experience.

"We've already seen strong performance across our Delta-8 line, and this gummy is a direct response to customer demand for more convenient, enjoyable, and effective ways to experience its benefits," said Lisa Nelson, President & CEO of CBD Life Sciences Inc. "As always, we're delivering a product that's backed by science, produced in-house, and driven by results."

Delta-8 THC: Expanding the Future of Functional Wellness
Unlike traditional Delta-9 THC, Delta-8 offers a milder, clearer psychoactive experience - making it a preferred option for wellness seekers, first-time users, and individuals looking for a balanced high without anxiety.

CBDL's newly formulated Delta-8 gummies are not just about effect - they're designed to deliver real therapeutic value. Below is a breakdown of the core wellness benefits supported by research and consumer feedback:

Pain Relief

• Engages the endocannabinoid system to help regulate pain
• May reduce inflammation that contributes to chronic discomfort

Anxiety & Stress Support

• Natural calming effects to help manage daily stress and reduce anxiety
• Promotes overall mood balance without sedation

Nausea Control

• Anti-emetic potential makes it a powerful option for those undergoing chemotherapy or other nausea-inducing treatments

Appetite Stimulation

• Ideal for individuals with appetite loss or dietary imbalances related to health conditions

Neuroprotective Potential

• Early research suggests Delta-8 THC may contribute to long-term brain health through its interaction with CB1 receptors

Made In-House. Backed by Lab Testing.
Unlike many mass-produced gummies on the market, CBDL maintains full control over every phase - from formulation to packaging - in its in-house manufacturing facility. Each batch is independently lab-tested to guarantee purity, potency, and compliance, giving consumers complete confidence in what they're consuming.

Strategic Growth for Shareholders & Stakeholders
Delta-8 THC products have already proven to be one of CBDL's strongest performing categories, and this launch further solidifies the company's aggressive expansion in the high-growth cannabinoid edible space. The market for Delta-8 continues to gain national momentum, with sales projections showing compound annual growth that far outpaces many traditional supplement sectors.

"This gummy is just one part of a much larger product ecosystem we're building - focused on in-demand cannabinoids, real health outcomes, and market scalability," said Nelson.

Product Details

• Product: Delta-8 THC Gummy
• Type: Vegan, In-House Formulated, Lab-Tested
• MG per Gummy: 500MG
• Availability: Launching via www.thecbdvault.com
• Flavors: Blue Razz & Strawberry

[Giants1967] $OODH Orion Announces Oklahoma Scoop Stack Royalty Acquisitions https://www.acce...

Giants1967 — 5/26/2025 8:53:25 AM

$OODH Orion Announces Oklahoma Scoop Stack Royalty Acquisitions
https://www.accessnewswire.com/newsroom/en/metals-and-mining/orion-announces-oklahoma-scoop-stack-royalty-acquisitions-1030938

[getlouied] $FBCD FBC Holding, Inc. (FBCD) Apparel Worn by Pro Athletes as Formrunner Gains...

getlouied — 5/20/2025 7:45:20 AM

$FBCD FBC Holding, Inc. (FBCD) Apparel Worn by Pro Athletes as Formrunner Gains Traction in Sports Culture

https://www.accessnewswire.com/newsroom/en/consumer-and-retail-products/fbc-holding-inc.-fbcd-apparel-worn-by-pro-athletes-as-formrunner-gains-1029570

Global streetwear market expected to surpass $220 billion by 2032 as limited drops and athlete interest drive demand for emerging brands.

SCOTTSDALE, AZ / ACCESS Newswire / May 20, 2025 / FBC Holding, Inc. (OTC PINK:FBCD), the parent company behind rising premium streetwear label Formrunner Apparel, is excited to announce growing organic interest from professional athletes, including several high-profile players from a major Arizona football team.

What started as a casual photoshoot with a few players quickly evolved into a powerful moment for the brand. After wearing the gear, those athletes walked away with bags of exclusive pieces-later followed by their teammates who sought out the brand independently. Some players have even made in-store purchases at Studio 22, Formrunner's flagship retail store in Chandler, Arizona.

"When athletes go out of their way to visit your storefront and buy your designs off the rack, it's a sign that your brand resonates," said Lisa Nelson, CEO of FBC Holding, Inc. "This wasn't a paid partnership-it was real, organic traction among people who shape culture."

Exclusivity Meets Influence

Formrunner's success is built on a foundation of limited edition drops, premium 100% cotton construction, and a no-restock model that fuels both scarcity and loyalty. With bold designs that intersect fashion, music, and sports, the label continues to carve out a lane in the competitive streetwear space.

The recent interest from professional athletes highlights Formrunner's growing influence-proving that peer-to-peer product adoption among trendsetters and public figures remains one of the most powerful drivers of modern fashion.

According to recent industry data, the global streetwear market is projected to exceed $220 billion by 2032, fueled by youth culture, exclusivity, and influencer adoption. Formrunner's momentum places FBC Holding, Inc. at the heart of this cultural shift.

Momentum & Expansion

The attention from athletes is just the beginning. FBC Holding is actively engaging with influencers, musicians, and cultural leaders to expand the brand's footprint and solidify its position as a national lifestyle brand. With plans underway for more retail locations and enhanced eCommerce logistics, the company is setting the stage for sustainable, high-margin growth.

Studio 22, located in Chandler, Arizona, has rapidly become a hub for creators, artists, and tastemakers. As both a retail space and cultural center, it embodies Formrunner's mission to honor legacy, build community, and drive innovation in fashion.

"We started Formrunner to honor a legacy and tell a story-and now that story is being worn by top athletes and tastemakers across the country," added Nelson. "This is just the beginning."

[rdkflorida2] LTUM >>> Confirmed with a friend. The largest lithium and rare earth metals in ...

rdkflorida2 — 5/13/2025 9:28:38 AM

LTUM >>> Confirmed with a friend. The largest lithium and rare earth metals in the U.S. are located in northern Nevada. (Maybe in the world). Almost all between Elko and the Oregon border. This is exactly where LTUM is doing their field work at this moment. IMHO, any significant finds by LTUM will send the pps soaring.

[rdkflorida2] LTUM>>>Solid state batteries are the future. QS, Quantum Scape, is using lithiu...

rdkflorida2 — 5/9/2025 2:34:21 PM

LTUM>>>Solid state batteries are the future. QS, Quantum Scape, is using lithium in gel form to eliminate/reduce risk of fire. New breakthrough using lithium in metal form coming. QS for solid state with their partnership with VW, and LTUM looking at increases in price for lithium and possible shortages by 2030. Maybe much earlier. Just a FYI.

Scientists blast through battery world record in major hope for breakthrough new technology

[rdkflorida2] Possible new finds/production? PPS could easily become a10x mover, imho. Lithi...

rdkflorida2 — 5/8/2025 12:00:08 PM

Possible new finds/production? PPS could easily become a10x mover, imho.

Lithium Corporation Commences 2025 Field Work

[rdkflorida2] LTUM ..... Had a move to over .06 recently on increased volume. Looks to be set...

rdkflorida2 — 5/6/2025 8:52:10 AM

LTUM ..... Had a move to over .06 recently on increased volume. Looks to be setting up for a bigger move UP. IMHO.

[getlouied] $CBDL CBD Life Sciences Inc. (CBDL) Announces New Manufacturing Deal With A Sou...

getlouied — 5/6/2025 8:31:14 AM

$CBDL CBD Life Sciences Inc. (CBDL) Announces New Manufacturing Deal With A Southwest-Based Company

accessnewswire.com

Strategic alliance positions CBDL for aggressive national growth through 100+ retail locations and new premium product lines

SCOTTSDALE, AZ / ACCESS Newswire / May 6, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL), a leading innovator in the CBD health and wellness space, is proud to announce a new strategic manufacturing partnership with Jeannie in a Bottle, a fast-growing Arizona-based CBD company with a national retail footprint.

This powerful collaboration will see CBDL formulating and manufacturing top-tier CBD products for Jeannie in a Bottle - a company with proven market traction and shelf presence in over 100 gas stations and convenience stores across the United States. The deal expands CBDL's manufacturing portfolio while opening the door to high-volume, recurring product orders tied to Jeannie's established consumer base and retail distribution network. Under this agreement, CBDL will take full control of the production, packaging, and labeling of a specialized line of high-potency CBD products exclusively for Jeannie in a Bottle - a strategic move expected to significantly boost CBDL's nationwide revenue stream through consistent retail orders and brand expansion.

"This partnership is a win-win - not just for CBDL and Jeannie in a Bottle, but for shareholders and customers alike," said Lisa Nelson, President & CEO of CBD Life Sciences Inc. "We're stepping into a high-velocity retail environment with a proven brand, and bringing our own formulation and production strengths to the table. This is the kind of alignment that accelerates revenue, reputation, and results."

With CBDL managing product development, formulation, and manufacturing, Jeannie in a Bottle is positioned to scale its product offerings faster than ever - offering convenience store customers across the country consistent, compliant, and highly effective CBD wellness solutions.

Why This Deal Matters for CBDL Investors:

Built-In Distribution Power: Jeannie in a Bottle's existing footprint includes over 100 retail stores nationwide - giving CBDL immediate access to one of the most dynamic and accessible sales channels in the country.
Revenue Acceleration Potential: With consistent monthly reorders expected, the deal strengthens CBDL's revenue pipeline through ongoing production contracts and retail partnerships.
Brand Alignment & Synergy: Jeannie in a Bottle has a strong reputation for customer satisfaction, quality products, and effective formulations - values that align perfectly with CBDL's mission and vision.
Retail Momentum: The convenience store and gas station channel continues to see increased demand for functional wellness products, with CBD offerings leading the surge in consumer interest.

CBD Life Sciences Inc. continues to execute on its aggressive growth roadmap through smart, synergistic partnerships like this one - pairing established retail reach with premium product manufacturing to scale impact and revenue in tandem. With more partnerships and product innovations on the horizon, CBDL is positioning itself to be a national force in the CBD industry.

[getlouied] $CBDL CBD Life Sciences Inc. (CBDL) Announces New Manufacturing Deal With A Col...

getlouied — 4/29/2025 8:44:18 AM

$CBDL CBD Life Sciences Inc. (CBDL) Announces New Manufacturing Deal With A Columbian Company

accessnewswire.com

New manufacturing deal positions CBDL to tap into the $4.9 billion Latin American CBD market, unlocking major revenue growth and accelerating international expansion.

SCOTTSDALE, ARIZONA / ACCESS Newswire / April 29, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL), a leading innovator in the cannabidiol (CBD) wellness industry, is proud to announce a major new manufacturing partnership with Thallos, a premier South American company headquartered in Colombia. Under this agreement, CBDL will take full control of the production, packaging, and labeling of a specialized line of high-potency CBD products exclusively for Thallos - a strategic move expected to significantly boost CBDL's global revenue streams.

CBDL is set to manufacture Thallos' flagship offerings, including a 2,000mg Pain Cream Salve available in both Mint and Cinnamon varieties, along with a 2,000mg CBD Tincture. These products will be produced entirely in-house at CBDL's state-of-the-art facilities, allowing the company to maintain strict quality assurance while maximizing manufacturing efficiencies.

With South America's CBD market projected to surpass $4.9 billion by 2028 and Colombia emerging as a major player, the opportunity is enormous. Due to current U.S. tariff impacts and regulatory hurdles, Colombian companies like Thallos face increasing challenges importing CBD goods. CBDL's ability to offer domestic U.S. manufacturing and distribution provides a turnkey solution, giving Thallos a competitive edge while delivering substantial new revenue for CBDL.

"This partnership is a game-changer for CBDL," said Lisa Nelson, CEO of CBD Life Sciences Inc. "By strategically positioning ourselves as the manufacturing engine for a growing South American brand, we're opening the door to scalable, recurring revenue and strengthening our position as a dominant force in the global CBD supply chain."

In addition to strengthening its financial foundation, this new international venture demonstrates CBD Life Sciences Inc.'s continued commitment to innovation, growth, and global leadership. CBDL is now uniquely positioned to leverage international partnerships, expanding its footprint into some of the fastest-growing markets in the world and setting the stage for record-breaking performance in 2025 and beyond.

[getlouied] CBD Life Sciences Inc. (CBDL) Announces Groundbreaking 100MG Full Spectrum CBD G...

getlouied — 4/22/2025 8:31:29 AM

CBD Life Sciences Inc. (CBDL) Announces Groundbreaking 100MG Full Spectrum CBD Gummy Geared Toward Mental Health & Focus

accessnewswire.com

With the global CBD market expected to exceed $60 billion by 2030, and the mental wellness industry surging past $500 billion, CBD Life Sciences Inc. (OTC:CBDL) is strategically positioning itself at the center of two of the fastest-growing markets in modern health.

SCOTTSDALE, AZ / ACCESS Newswire / April 22, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL) a leader in cannabinoid-driven health innovation - proudly announces the launch of its most anticipated product to date: a high-dosage 100MG Full Spectrum CBD Gummy, meticulously formulated to support mental health, daily focus, and emotional well-being.

Available in mouth-watering Crisp Green Apple and Wild Blueberry flavors, this isn't your average CBD gummy. It's a next-generation wellness tool - designed not only to relax the body but to sharpen the mind. Crafted with full-spectrum cannabinoids, these gummies are being positioned as a natural ally in the pursuit of mental clarity, balance, and daily productivity.

"Mental health isn't a trend - it's a global crisis. And people are tired of band-aid solutions," said Lisa Nelson, President & CEO of CBD Life Sciences Inc. "This product was built to empower people who want to feel better and function better - without the side effects of traditional pharmaceuticals. It's a powerful, natural alternative that speaks directly to the stress, anxiety, and attention struggles millions face every day."

Lab tested and verified with Certificates of Analysis (COAs), this 100MG gummy represents the company's deepest push yet into the lucrative mental wellness category. Unlike many low-dose competitors, CBDL's bold formulation is made for people who need real results - entrepreneurs, creatives, students, parents, and professionals looking to stay in control of their mood and mindset.

Early conversations with several wellness clinics and mental health centers are already in progress, exploring how this high-potency gummy could be integrated into patient routines. While no formal agreements have been made, the demand is clear: health professionals are actively seeking natural, high-quality, lab-verified CBD options to complement modern mental wellness protocols.

CBDL is rapidly building a portfolio that taps into high-value niches: from pain relief and nano-enhanced beverages to functional CBD coffee creamers and now, this cutting-edge product for mental clarity. The company's ability to stay ahead of trends and deliver results has attracted attention from both investors and the wellness industry.

"We're not trying to follow the market - we're reshaping it," Nelson added. "With this launch, we're doubling down on our belief that the future of wellness lies in functional, focused, and effective cannabinoid products."

This release is a bold statement to shareholders and the industry: CBD Life Sciences Inc. is serious about mental health. The company's momentum continues to build, and with this new launch, they're inviting wellness professionals, retail buyers, and everyday users to experience the next level of what CBD can offer.

The 100MG Mental Health Gummies are available now, with full lab reports and wholesale interest forms available on the company's website.

For product information, COAs, or wholesale inquiries, please visit www.thecbdvault.com.

[rdkflorida2] LTUM>>>>Per poster on another board. Only one fully operational rare minerals m...

rdkflorida2 — 4/18/2025 10:37:11 AM

LTUM>>>>Per poster on another board. Only one fully operational rare minerals mine in the U.S. China is cutting of shipments and tariffs on other countries. LTUM move up may just be the beginning. I remember MVIS going from .15 to $28. Maybe LTUM moves to over a $1.00. TWT.

[Giants1967] OTC NEWS RECAP $SWISF Attended The Spring MicroCap Summit prnewswire.com $YGT ...

Giants1967 — 4/18/2025 8:54:15 AM

OTC NEWS RECAP

$SWISF Attended The Spring MicroCap Summit
prnewswire.com

$YGT $YGTFF Secures C$1.84M as Osisko Gold (NYSE: $OR) Commits $2M

finance.yahoo.com

$PNPNF $PNPN Power Metallic Expands the Tiger Zone
prnewswire.com

$CSDX Strategic Financing:
accessnewswire.com

$INND Shareholder Letter

world.einnews.com

$RITE CEO Posted a Shareholder Memo recapping 1 st quarter 2025

mineral-rite.com

$INCC Strategic partnership with Marcum's Nursery
accessnewswire.com

$HYEX Reported preliminary results for the first quarter ended March 31, 2025.
accessnewswire.com

[rdkflorida2] LTUM>>>Getting some play today. I read that lithium will be used in solid state...

rdkflorida2 — 4/17/2025 3:13:45 PM

LTUM>>>Getting some play today. I read that lithium will be used in solid state batteries in gel form per poster on another board. I'm in around .04 but not too many shares. On my watch list.

[getlouied] $MDCE Celebrates $25 Million Authenticated, Targets Patent on AI Innovation ...

getlouied — 4/15/2025 9:40:47 AM

$MDCE Celebrates $25 Million Authenticated, Targets Patent on AI Innovation

https://www.prnewswire.com/news-releases/mdce-celebrates-25-million-authenticated-targets-patent-on-ai-innovation-302428771.html

MESA, Ariz., April 15, 2025 /PRNewswire/ -- Medical Care Technologies Inc. (OTC PINK:MDCE), a technology-focused company in the sports collectibles space, is proud to announce that its subsidiary Real Game Used (RGU) has surpassed $25 million in authenticated memorabilia and is now preparing to file a patent for its artificial intelligence-based authentication process — the first of its kind in the sports memorabilia industry.

This AI process, developed by Real Game Used, utilizes machine learning and advanced imaging to analyze wear patterns, materials, and provenance data with precision and consistency. The upcoming patent filing represents not only a milestone in MDCE's commitment to innovation but also a potential licensable asset that could be made available to authenticators, appraisers, hobby shops, and auction houses — setting a new standard for the industry.

"Our goal is to empower the memorabilia ecosystem with technology that adds confidence, transparency, and scalability," said Marshall Perkins, CEO of Medical Care Technologies Inc. "This AI-based process isn't just a win for us — it could become a vital tool for the industry as a whole."

As a tech-driven pioneer, RGU fits strategically under the Medical Care Technologies umbrella alongside its existing subsidiary Infinite Auctions, an established online auction house known for selling high-end sports and entertainment memorabilia. Together, the companies place MDCE at the forefront of innovation and authenticity in a multibillion-dollar global collectibles market.

Looking ahead, Medical Care Technologies Inc. is actively exploring the potential to bring additional synergistic companies into its portfolio, as it continues to grow its influence across the collectibles and memorabilia space.

[getlouied] $CBDL CBD Life Sciences Inc. (CBDL) Company Online Sales Up 500% accessnewswir...

getlouied — 4/10/2025 8:39:48 AM

$CBDL CBD Life Sciences Inc. (CBDL) Company Online Sales Up 500%

accessnewswire.com

With the global wellness industry exploding past $7 trillion, CBDL positions itself at the intersection of CBD, mushrooms, and modern healing - delivering real results and red-hot returns.

SCOTTSDALE, AZ / ACCESS Newswire / April 10, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL) is thrilled to announce a 500% increase in online sales this past quarter, catapulting the company into a new phase of growth as it rides the tidal wave of a rapidly expanding global wellness economy.

This milestone reflects the company's relentless focus on innovation, clean ingredients, and product efficacy. From cutting-edge CBD topicals to adaptogenic mushroom blends, CBDL is gaining significant traction in both consumer markets and investor circles.

"We're not just selling CBD anymore," said CEO Lisa Nelson. "We're creating a new category of functional wellness - one that blends the healing powers of CBD, mushrooms, and natural ingredients backed by science and built for today's lifestyles."

Positioned in the Heart of a $7 Trillion Wellness Boom
The wellness industry is booming - valued at $7.1 trillion globally, with natural health solutions like CBD and functional mushrooms taking center stage. CBDL is uniquely positioned at this intersection, offering products that tap into two of the most explosive markets in the world:

The CBD market, projected to exceed $60 billion by 2030
The functional mushroom market, expected to surpass $24 billion by 2032

CBD Life Sciences Inc. is going beyond traditional CBD by launching wellness-forward formulations that include Reishi, Lion's Mane, and Ashwagandha - powerful adaptogens known for reducing stress, improving focus, boosting immunity, and fighting inflammation. The company's line of CBD Kava & Kratom Shots is also gaining momentum as a natural alternative to caffeine, energy drinks, and synthetic stress relief.

CBDL's Momentum is Just Getting Started:

500%+ online sales growth in Q1 2025
Top-sellers: 3000MG Pain Relief Cream, CBD Kava & Kratom Shots, Mushroom Wellness Blends
Retail Expansion:
- Now selling on Walmart Marketplace
- Products available through DoorDash in select markets
- More e-commerce and delivery partnerships in development
Innovative Product Development:
- Proprietary Nano-CBD Technology for maximum bioavailability
- Launch of adaptogenic mushroom products including Reishi, Lion's Mane, and Ashwagandha
Domestic Production & Compliance:
- All products made in the USA
- Third-party tested for quality and consistency
- Clean-label ingredients, no artificial fillers

For Investors
CBD Life Sciences Inc. is not just scaling - it's setting the pace. By strategically expanding into multiple billion-dollar wellness verticals, CBDL is leveraging its momentum to build a brand that is future-proof, health-focused, and ready for mass market adoption.

With more consumers turning to plant-based, functional wellness solutions every day, CBDL stands at the forefront of a generational shift in how people approach health and healing.

For investors seeking to get in on the ground floor of the next wave in natural wellness, CBD Life Sciences Inc. is the name to watch.

[okavango] $TWOH on fire last week. Too late? I wouldn't know. GL.

okavango — 4/7/2025 2:02:29 AM

[getlouied] $CBDL CBD Life Sciences Inc. (CBDL) Powers Forward with Disruptive Brain-Boosti...

getlouied — 4/1/2025 3:45:27 PM

$CBDL CBD Life Sciences Inc. (CBDL) Powers Forward with Disruptive Brain-Boosting Mushroom Applications

accessnewswire.com

The global functional mushroom market is projected to reach $19.3 billion by 2030, driven by cutting-edge research revealing their potential to enhance memory, nerve growth, and overall cognitive health.

SCOTTSDALE, AZ / ACCESS Newswire / April 1, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL) is making bold strides into the booming functional mushroom sector, positioning itself at the forefront of a revolution that is reshaping cognitive health and wellness. As the demand for natural, scientifically backed solutions grows, CBDL's strategic expansion into brain-boosting mushroom applications signals a major step forward in harnessing the power of nature to optimize mental performance, longevity, and overall well-being.

Unlocking the Power of Brain-Boosting Mushrooms

Scientific studies have revealed that certain mushrooms, particularly Lion's Mane (Hericium erinaceus), contain bioactive compounds that support nerve regeneration and improve cognitive function. Researchers at the University of Queensland recently identified specific compounds that promote nerve growth and enhance memory, validating what ancient medicine has long recognized. Additionally, emerging studies suggest that regular mushroom consumption may reduce the risk of neurodegenerative diseases such as Alzheimer's and Parkinson's.

By incorporating these groundbreaking discoveries into its product development pipeline, CBDL is setting the stage for an entirely new category of wellness products designed to support brain function, enhance learning ability, and provide neuroprotection against age-related decline. This move is more than just an expansion-it's an investment in the future of cognitive health, offering consumers an alternative to synthetic drugs with potentially harmful side effects.

A Multi-Billion Dollar Market with Limitless Potential

The global market for functional mushrooms is expanding at an exponential rate, with a projected value of $19.3 billion by 2030. Investors are taking notice as mushroom-based products gain mainstream traction, with companies developing innovative applications in health, sustainability, and even technology. The surge in consumer interest, coupled with increased scientific validation, has created a perfect storm for industry disruption, and CBDL is capitalizing on this momentum.

CBDL's strategic focus on this sector presents an enormous revenue-generating opportunity, aligning with the company's mission to pioneer the next frontier of holistic wellness. The market potential extends far beyond supplements-mushrooms are now being used in sustainable product development, biodegradable materials, and even robotics. Researchers have successfully harnessed electrical signals from mycelium to engineer fungi-controlled robotics, further proving that the future of innovation is deeply intertwined with mushrooms.

Addressing Public Health & Safety Concerns

With the rising popularity of mushroom-based wellness products, CBDL remains committed to safety and regulatory compliance. While some psychedelic mushroom edibles have raised concerns due to lack of regulation, CBDL ensures that its products are developed with strict quality control measures, harnessing only scientifically backed, non-psychedelic mushroom compounds for cognitive enhancement and neurological support.

Furthermore, as the FDA investigates safety concerns surrounding unregulated psychoactive mushroom products, CBDL is dedicated to setting the industry standard for transparency, efficacy, and consumer trust. This commitment reassures both consumers and investors that CBDL is not only a leader in innovation but also in safety and responsibility.

Why Shareholders Should Pay Attention

CBDL's expansion into the brain-boosting mushroom market represents a forward-thinking move that aligns with skyrocketing demand and industry-wide advancements. This initiative is not just about capitalizing on a growing trend-it's about positioning CBDL as a dominant force in a rapidly evolving sector with unlimited scalability. The ability to integrate mushrooms into multiple verticals, from health and wellness to sustainability and technology, makes this a game-changing pivot that opens the door to exponential growth and diversified revenue streams.

By investing in cutting-edge research, sustainable development, and high-quality formulations, CBDL is poised to capitalize on this revolutionary movement-bringing unparalleled value to both consumers and shareholders alike. The company's forward momentum reflects a vision beyond CBD and cannabis, solidifying its role as an innovator in the broader alternative wellness space.

As the world moves towards natural, effective, and sustainable health solutions, CBDL is not just following the trend-it is shaping the future. This latest venture into functional mushrooms cements the company's commitment to long-term growth, scientific excellence, and industry leadership.

Sky News Mushroom Video: pr.report

[getlouied] $CBDL CBD Life Sciences Inc. (CBDL) Launches Passion Fuel Cordyceps Complex - A...

getlouied — 3/27/2025 3:02:06 PM

$CBDL CBD Life Sciences Inc. (CBDL) Launches Passion Fuel Cordyceps Complex - A Powerful Sexual Enhancement Supplement

accessnewswire.com

The global sexual wellness market is projected to surpass $125 billion by 2026, with the supplement industry experiencing rapid growth as consumers seek natural solutions for enhanced performance and vitality.

SCOTTSDALE, AZ / ACCESS Newswire / March 27, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL) is making waves in the booming health and wellness industry with the launch of its latest breakthrough product: Passion Fuel Cordyceps Complex. This cutting-edge supplement is designed to supercharge libido, enhance stamina, improve blood flow, and optimize overall performance, providing an all-natural solution for individuals looking to elevate their intimate and athletic experiences.

Each serving of Passion Fuel Cordyceps Complex delivers a potent 300mg dose of pure Cordyceps extract (150mg per pill, 2 pills per serving)-a revered medicinal mushroom known for its powerful adaptogenic properties. Backed by scientific research, Cordyceps has been shown to increase oxygen uptake, improve circulation, boost testosterone levels, and enhance endurance, making it a game-changer for those seeking peak physical and sexual performance.

"This launch is a major milestone for CBDL as we continue to expand our product line with high-demand, science-backed formulations," said Lisa Nelson, President & CEO of CBD Life Sciences Inc. "With the sexual wellness market projected to skyrocket past $125 billion, we are positioning ourselves at the forefront of an industry that is set to redefine natural health solutions. Passion Fuel Cordyceps Complex has the potential to generate significant revenue streams and open the door to lucrative partnerships in both the supplement and pharmaceutical sectors."

Unleashing the Power of Cordyceps for Peak Performance Passion Fuel Cordyceps Complex offers a wide range of benefits, including:

Enhanced libido & improved erectile function - Naturally increases testosterone and supports sexual health.
Boosted stamina & athletic performance - Increases ATP production, delivering sustained energy and endurance.
Improved blood flow & circulation - Supports heart health and oxygenation for peak physical function.
Optimized hormonal balance - Helps regulate cortisol and stress levels, fostering overall well-being.
Increased energy & vitality - Fights fatigue and enhances metabolic efficiency for all-day performance.

A Strategic Move for Future Growth The release of Passion Fuel Cordyceps Complex aligns with CBDL's aggressive expansion strategy, tapping into an industry that continues to experience unprecedented demand. With the dietary supplement market exceeding $177 billion in 2023, CBDL is capitalizing on a golden opportunity to deliver premium, plant-based formulations that consumers trust.

As the company accelerates its growth trajectory, Passion Fuel Cordyceps Complex is set to be distributed across major online marketplaces, wellness retailers, and direct-to-consumer platforms. CBDL is also actively exploring strategic partnerships to bring this powerhouse supplement to new audiences globally.

[Giants1967] $RITE 3/5 News finance.yahoo.com

Giants1967 — 3/7/2025 10:12:40 AM

[Giants1967] OTCWeekly $YGT.V $YGTFF Gold Terra Wedge Drilling Progressing Well accessne...

Giants1967 — 2/28/2025 10:23:41 AM

OTCWeekly

$YGT.V $YGTFF Gold Terra Wedge Drilling Progressing Well
accessnewswire.com

$ECGS Strategic Acquisition:
prnewswire.com

$UCLE US Nuclear Corp. First Quote Requests for 50-100 Gauntlet Sentry Radiation Detection Systems for Border Security
newmediawire.com

$VRHI Veri Medtech Reaches 1.3 million Patient Registrations
globenewswire.com

[getlouied] $CBDL CBD Life Sciences Inc. (CBDL) Launches Mushroom Powder Capsules accessn...

getlouied — 2/26/2025 9:10:18 AM

$CBDL CBD Life Sciences Inc. (CBDL) Launches Mushroom Powder Capsules

accessnewswire.com

The Global Functional Mushroom Market is Set to Surpass $19 Billion by 2030—CBDL Enters the Booming Industry with Premium Mushroom Capsules for Cognitive Enhancement, Immune Support & Longevity!

SCOTTSDALE, ARIZONA / ACCESS Newswire / February 26, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL) is making a bold move into the multi-billion-dollar functional mushroom market with the official launch of its Mushroom Powder Capsules-a powerful, all-natural supplement designed to elevate brain function, enhance energy, boost immunity, and optimize overall wellness.

This premium formulation combines five of the most researched and revered medicinal mushrooms:

Lion's Mane - Known for its neuroprotective properties, enhances cognitive function, memory, and focus.
Cordyceps - Increases stamina, improves athletic performance, and supports lung function.
Reishi - Helps reduce stress, promotes better sleep, and strengthens the immune system.
Maitake - Supports metabolic health and helps regulate blood sugar levels.
Turkey Tail - Packed with antioxidants and polysaccharides that fortify gut health and boost immunity.

With scientific studies confirming the vast health benefits of these mushrooms, CBDL is positioning itself at the forefront of the natural health revolution. The global demand for functional mushrooms has skyrocketed due to their ability to combat stress, enhance brain power, and promote longevity-aligning perfectly with consumer trends toward holistic wellness and plant-based supplementation.

A Massive Revenue Opportunity

By launching into the functional mushroom industry, CBDL is tapping into a market projected to exceed $19 billion by 2030, with a CAGR of 9.1%. This strategic expansion will drive substantial new revenue streams and significantly increase consumer engagement with the brand.

CBDL's Mushroom Powder Capsules will be available through its existing sales channels, including direct-to-consumer e-commerce and select retail partners, with further distribution expansion planned as demand grows.

"This launch marks a pivotal moment for CBDL as we expand beyond CBD and into the booming functional mushroom sector," said Lisa Nelson, CEO of CBD Life Sciences Inc. "Our goal is to provide top-tier, science-backed natural solutions that enhance everyday health while capitalizing on one of the fastest-growing wellness trends in the world."

CBDL is committed to aggressive marketing, expanding its direct sales reach, and forming strategic partnerships to position its Mushroom Powder Capsules as a category leader. With consumer interest surging and scientific validation mounting, CBDL's foray into functional mushrooms represents not just an innovative product launch-but a major step toward long-term profitability and market dominance.